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Abstract 
The effect of the calcimimetic cinacalcet on cardiovascular disease in patients 
undergoing hemodialysis with secondary hyperparathyroidism (sHPT) was 
evaluated in the EVOLVE trial.  This was the largest (in size) and longest (in 
duration) randomized controlled clinical trial undertaken in this population.  
During planning, execution, analysis and reporting of the trial many lessons were 
learned, including those related to the use of a composite cardiovascular primary 
endpoint, definition of endpoints (particularly heart failure and severe unremitting 
HPT), importance of age for optimal stratification at randomization,  use of 
unadjusted and adjusted intention-to-treat analysis for the primary outcome,  how 
to respond to a lower than predicted event rate during the trial,  development of a 
pre-specified analytic plan that accounted for non-adherence and for co-
interventions that diminished the power of the trial to observe a treatment effect, 
determination of the credibility of a subgroup effect,  use of adverse effects 
database to investigate rare diseases, collection of blood for biomarker 
measurement not designated prior to trial initiation,  and  interpretation of the 
benefits to harms ratio for individual patients.  It is likely that many of these issues 
will arise in planning of future trials in chronic kidney disease. 
 
 
4 
 
Introduction 
The Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular 
Events (EVOLVE) trial was the largest (N = 3883) and longest (median follow-up 
50.5 months) randomized controlled trial (RCT) undertaken in patients receiving 
hemodialysis (1).  The hypothesis tested was that the calcimimetic cinacalcet, 
compared to placebo, would reduce the risk of death or nonfatal cardiovascular 
events among patients with sHPT (intact parathyroid hormone (iPTH) ≥ 300 
pg/mL) who were undergoing hemodialysis.  In the primary unadjusted intention-
to-treat (ITT) analysis, cinacalcet did not significantly reduce the risk of the 
composite cardiovascular (CV) primary outcome, but there were a number of 
design and analysis issues that should be considered when interpreting the results.  
In this review we discuss study challenges faced, decisions made and lessons 
learned from EVOLVE, and how they may be relevant in the design of future trials 
in dialysis and chronic kidney disease (CKD). 
Choice, definition and analysis of primary events. 
Composite Primary Outcome.  The primary endpoint was a composite comprised 
of all-cause mortality or non-fatal CV events (myocardial infarction, 
hospitalization for unstable angina, heart failure or peripheral vascular disease).  
These CV events may occur via different pathophysiological pathways:  
myocardial infarction and unstable angina are principally caused by atherosclerotic 
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vascular disease, while heart failure results from cardiomyopathy (with systolic or 
diastolic dysfunction) for which arteriosclerosis and uremia are predisposing 
factors (2).  Peripheral vascular disease is often atherosclerotic, but distal occlusive 
disease, particularly of the lower extremities, is often accompanied by dense 
calcific arteriosclerosis.  The CV events were chosen because we hypothesized that 
cinacalcet would (A) reduce heart failure and death by reducing medial 
calcification of conduit arteries (thus improving vascular compliance and 
decreasing LV hypertrophy) and by decreasing the potential cardiotoxic effect of 
PTH, (B) reduce atherosclerotic events by decreasing intimal calcification of 
atherosclerotic stenoses (3).  If the endpoint had been mortality alone a much 
larger sample size would have been necessary. 
Inclusion of overall mortality in the composite outcome is an issue because CV 
mortality would likely be modified by cinacalcet, in contrast to non-CV mortality. 
We included overall mortality in the primary outcome because we thought it 
necessary to demonstrate that the intervention did not cause unanticipated serious 
adverse effects on non -CV outcomes (such as cancer or death after fracture). 
 
Post-hoc evaluation of the treatment effects on CV events using multi-variable 
adjusted ITT analysis showed a relative hazard of 0.88 (95% confidence intervals 
(CI):  0.76 to 1.01) for time to first atherosclerotic event, 0.79 (95% CI 0.66 to 
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0.96) for heart failure, and 0.79 (0.64 to 0.98) for sudden death, the latter 2 events 
considered to be outcomes of non-atherosclerotic disease (4).  The 95% CI of the 
atherosclerotic and non-atherosclerotic outcomes overlap, but the magnitude of the 
relative hazard for heart failure and sudden death are consistent with the hypothesis 
that cinacalcet may act through the non-atherosclerotic pathway.  As medial 
calcification and intimal calcification may well be different entities in CKD (5), 
this suggests that the dominant effect of cinacalcet may be through the inhibition of 
medial calcification. 
Definition of outcomes.  Clinically relevant, precisely defined, reproducible end 
points with central adjudication are necessary in RCTs that aim to change clinical 
practice (6).  Death and major atherosclerotic CV events fulfill these criteria, but 
the definition of heart failure in CKD has been problematic because of the 
difficulty in differentiating salt and water overload from impaired left ventricular 
function. This issue was recently crystalized by the proposal for a functional 
classification system of heart failure in patients with end-stage renal disease 
(ESRD) (7).  This system may be limited by the cost of echocardiography and lack 
of specificity of dyspnea relief by dialysis for diagnosis of heart failure.    
In patients receiving dialysis, heart failure has been defined as dyspnea with at 
least two of the following four manifestations:  bilateral basilar rales on physical 
exam, raised jugular venous pressure, interstitial edema on chest x-ray, and 
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increased upper pulmonary vessel diameter on chest x-ray (8).  The presence or 
history of heart failure was associated with an almost 2-fold increase in mortality 
(8).  In EVOLVE, we used a similar definition to that of  Harnett et al. (8) but 
added an additional clause to improve specificity:  the patient also was required to 
have received mechanical ultrafiltration or hemodialysis.  Nonetheless, the event 
adjudication committee confirmed the diagnosis of heart failure in only about half 
of heart failure events submitted by the local investigators, a result lower than that 
observed in high risk patients with hypertension (9).  This lack of certainty in the 
diagnosis of heart failure may limit study power because the event rate may be 
lower than anticipated, and misclassification may limit the capacity to identify a 
treatment effect.  A similar misreporting of myocardial endpoints occurred in the 
PARAGON-B and PURSUIT trials where investigators misreported myocardial 
infarction and points, but most later agreed with clinical events committee 
assessments (10, 11).  
Endpoint with selection bias.  Certain end points for mineral and bone disease in 
CKD are also problematic.  For example, the endpoint for severe HPT could be 
parathyroidectomy (PTX) but severe PTH may or may not be treated with PTX.  
PTX was a secondary endpoint in EVOLVE but prior to starting the study it was 
evident that the criteria by which physicians selected PTX for the treatment of 
sHPT varied widely across the world, and no criteria for PTX were provided by the 
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trial protocol.  Factors associated with PTX during the trial indicated selection 
effects and included younger age, female sex, higher body mass index, markers of 
co-morbidity (no history of valvular disease or angina or peripheral vascular 
disease), higher serum calcium and higher PTH; the use of PTX also varied widely 
by country of origin (lowest rates in USA) (12).  In addition, PTX was performed 
at an advanced phase of sHPT:mean PTH was 1872 pg/mL and serum calcium 
10.3 mg/dL (2.58 mmol/L) prior to PTX (12).  As there were likely to be additional 
patients who were not selected for PTX who might have undergone  PTX but did 
not because of various reasons unrelated to disease severity (e.g., surgeon or 
patient reluctance, no trained surgeon available), we defined an outcome before the 
trial was completed which we termed severe unremitting HPT, which included 
PTX or the presence of severe HPT with hypercalcemia (iPTH > 1000 pg/mL with 
serum calcium > 10.5 mg/dL (2.61 mmol/L) on two consecutive occasions or iPTH 
> 1000 pg/mL with serum calcium > 10.5 mg/dL (2.61 mmol/d) on one occasion 
and subsequent use of commercial (off-protocol) cinacalcet within two months of 
laboratory assessment).  Although hypercalcemia is a biochemical endpoint its 
occurrence implies an advanced phase of HPT, and clinical practice supports PTX 
in this scenario.  In the placebo group, severe unremitting HPT occurred in 24.3% 
(n=470), of whom 59% (n=278) had PTX.  The relative hazard (cinacalcet versus 
placebo) for severe unremitting HPT was 0.43 (95% CI 0.37 to 0.50).  This relative 
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hazard was similar whether baseline iPTH was mildly or markedly elevated but the 
number of events prevented increased as iPTH increased (12). 
Lessons from EVOLVE concerning choice and definitions of endpoints are 
presented in Table 1. 
Imbalance in baseline clinical characteristics.  Despite enrolling 3883 patients 
there was a 0.8 years difference in mean age at baseline and a 1 year difference in 
median age (55 versus 54 years), an occurrence that confounded the primary 
outcome (1).  This chance imbalance in a major prognostic factor for CV events 
necessitates covariate adjustment (13).  In the pre-specified primary analysis using 
an unadjusted intention-to-treat (ITT) analysis, the relative hazard was 0.93 (95% 
confidence interval (95% CI): 0.85 to 1.02), and the pre-specified multivariable 
adjusted ITT relative hazard was 0.88 (0.80 to 0.98).  It is likely that the observed 
age imbalance occurred by chance as the likelihood of imbalance is dictated by the 
population standard deviation (SD) for age and sample size.  The probability of an 
age difference of >0.8 years occurring in EVOLVE was 0.08, as the SD was 14 
and sample size 3883.  Owing to more restrictive inclusion criteria and older 
patients enrolled, the SD for age was narrower in SHARP (12 years) (14) and 
TREAT (10 years) (15), where the probability of observing an age difference (by 
chance) of >0.8 years between groups was 0.04 and 0.01, respectively. 
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CONSORT recommends reporting both unadjusted and adjusted analyses and 
stating whether the adjusted analysis was planned (16).  Although substantial 
variation exists in handling of baseline covariates in RCTs (17), covariate 
adjustment improves treatment effect estimation accuracy and statistical power, 
and hence should be performed when strong prognostic factors are observed or 
anticipated (11, 18). 
Lessons concerning imbalance in baseline covariates are presented in Table 2. 
Threats to statistical power 
The major causes of reduction in statistical power in EVOLVE were a lower than 
predicted primary composite event rate, discontinuation of study drug, particularly 
due to adverse effects in the cinacalcet group and failure to achieve control of 
sHPT in the placebo group, and PTH-lowering co-interventions that were applied 
disproportionately in the placebo group (i.e., parathyroidectomy, kidney 
transplantation, and use of commercial cinacalcet) (Figure 1).   
Event rate.  We calculated the sample size on the basis of the following 
assumptions:  an annual rate of the primary composite endpoint of 23.2% in the 
placebo group, a 20% treatment effect, a 1.5-year enrollment period, a 4-year total 
study duration, an annual rate of loss to follow-up of 1%, an annual rate of dropout 
(withdrawal from active treatment before a primary event) of 10% in the cinacalcet 
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group, and a rate of drop-in (use of commercially available cinacalcet before a 
primary event) of 10% in the placebo group.  On the basis of a two-sided log-rank 
test for equality of survival functions, accounting for planned interim analyses with 
an overall alpha level of 0.05, we determined that a primary event would need to 
occur in 1882 patients in order to ensure a power of approximately 90% (1).   
We estimated event rates by integrating data from phase 3 short- and medium-term 
RCTs comparing cinacalcet to placebo, as well as the observational data linking 
expected changes in PTH, calcium, and phosphorus within components of the 
primary composite endpoint.  After it became apparent that the overall (blinded) 
event rate was below 20.8%, we extended the trial by 16 months to allow for 
accrual of the requisite number of events.  The actual annual event rate in the 
placebo group was 15.5% (19). 
The event rate in the placebo arm of RCTs is frequently lower than predicted (20).  
When it became apparent that the primary composite event rate in EVOLVE was 
below that anticipated, the choice of intervention was to increase the number of 
enrolled subjects or to extend the duration of trial follow-up.  The first choice 
would have entailed re-engaging enrollment teams in dialysis units already 
extended by their contribution to EVOLVE and would have been more costly.  The 
decision was made to extend follow-up.  While additional events were expected to 
accrue over time, adherence with the intervention waned and more PTH-lowering 
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interventions were instituted (i.e., kidney transplantation, PTX and use of 
commercial cinacalcet) particularly in the placebo group.  High attrition of subjects 
from and drop-in to the intervention group eroded the original planned power of 
EVOLVE in such a manner that extension of the trial was of little benefit in 
identifying a treatment effect.  
Lessons:  
1. Event rate estimates in the sample size calculation should be conservative. 
2. If the event rate is lower than predicted and non-adherence during the trial 
(especially over time) is likely, then enrollment of more patients is generally 
preferable to extending follow-up. 
 
Non-adherence.  In the cinacalcet group, median time in the trial was 50.6 months 
and time on drug was 21.2 months.  Corresponding times for the placebo group 
were 50.4 and 17.5 months.  Time to first discontinuation of study drug for 
protocol-specified reasons was similar in both cinacalcet and placebo groups, but 
for non-protocol specified reasons it was significantly higher in the placebo group, 
driven by the fear of severe unremitting HPT (1).  In the placebo group, drug was 
discontinued for adverse events in 11.8%, compared with 15.8% in the cinacalcet 
group.  Some of this discontinuation was anticipated.  The “drop-in” rate was 
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expected to be 10%/year and the observed rate was 7.4%/year.  The “drop-out” rate 
was derived from discontinuation rates observed in prior cinacalcet RCTs and was 
higher than anticipated:  expected 10% and observed 27.3% per year.  This may 
have occurred because of the long-term nature of the trial amplifying the impact of 
kidney transplantation, PTX and use of commercial cinacalcet, and of comorbidity 
predisposing to study drug discontinuation because of adverse events and fear of 
severe HPT. 
 Drug discontinuation was a more important factor in diminishing the power of the 
study than the  lower -than- predicted event rates .The increase in sample size 
necessary in the presence of x% discontinuation can be estimated as the reciprocal 
of (1-x) squared .Hence, with 40% discontinuation at the trial mid-point, the 
sample size necessary  to maintain study power at the level planned was about 
three times bigger than planned.  
 
An analytic plan to take account of non-adherence in the estimates of the treatment 
effect was pre-specified.  It included lag censoring, iterative parameter estimate 
(IPE) and inverse probability of censoring weights (IPCW).  Lag censoring 
analysis uses data censored at a pre-specified time point.  In EVOLVE we had pre-
specified the lag time to be 6 months after cinacalcet was discontinued to account 
for the possibility that the drug had persistent effects.  Although lag censoring 
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preserves randomization, there may be informative bias if non-adherent patients 
(compared to adherent patients) have different prognostic characteristics associated 
with primary endpoint (21).  This methodologic weakness also occurs with the IPE 
method.  However the IPCW is not prone to informative bias (22). 
The IPCW approach censors data when non-adherence occurs.  For patients who 
were adherent and had similar characteristics to those who were not, IPCW assigns 
larger weights to these patients to “re-create” the population that would have been 
observed (22) (Figure 2).  Weights are calculated based on the inverse of the 
probability that patients remain adherent using a logistic regression model.  The 
final relative hazard is derived from a weighted regression model.  In EVOLVE 
age, sex, race, country, diabetes history, randomized treatment group, time 
dependent covariates of PTH, and the adverse events of hypocalcemia and 
nausea/vomiting were used in the logistic regression model to estimate the 
probability of adherence (22).  The IPCW method is sensitive to the number of 
non-adherent patients, assumes there are no unknown confounders and is 
computationally difficult.  Nonetheless, it is accepted by many health agencies.  
The relative hazard was 0.81 using IPCW (Table 3). 
Impact of co-interventions.  Before the trial started, it was clear that three co-
interventions that lower PTH – kidney transplantation, PTX and use of commercial 
cinacalcet – could diminish the treatment effect of cinacalcet, particularly if they 
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were delivered more frequently in the placebo group, as was expected for the latter 
two.  We considered including PTX in a composite endpoint, but were concerned 
about the lack of pathophysiological concordance for PTX and CV events (see 
above).  We considered censoring follow-up time after kidney transplantation or 
PTX, but were concerned about introducing bias, in that patients who were too ill 
would be unlikely to receive either of these two interventions.  Instead we pre-
specified estimates of the treatment effect once follow-up time after these three 
PTH-lowering interventions was censored.  Table 3 shows that the relative hazard 
was 0.90 when censoring occurred at either of these three co-interventions, and 
0.84 with censoring of time after any one of these co-interventions (1). 
Table 4 outlines lessons concerning the analytic plan for non-adherence and co-
interventions. 
Subgroup effects.  We pre-specified seven subgroup analyses including age ≥65 
and <65 years.  The relative hazard for the primary endpoint using ITT was 0.74 
(0.63 to 0.86) in the older group and 0.99 (95% CI 0.88 to 1.11) in the younger 
group (19).  There was a 27% reduction in mortality in patients > 65 years (p 
<0.001).  The test of treatment x age interaction was significant (p=0.03, using age 
as a continuous variable, p=0.007 when age was dichotomized at 65 years).  The 
age modification of the treatment effect was partly related to (1) 3-fold higher rates 
of kidney transplantation and PTX in younger patients, co-interventions that 
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limited detection of a treatment effect, (2) lower baseline CV disease in younger 
patients limiting the potential of cinacalcet to decrease CV events rates, and (3) 
lower CV event rates that decreased the power to observe an effect (19). 
Criteria by which to evaluate the credibility of subgroup effects have been 
published (23). Table 5 outlines the lessons from EVOLVE concerning the age 
subgroup effect. 
Capture of rare diseases.  RCTs collect accurate data on pre-determined endpoints 
reviewed by an event adjudication committee, but in addition substantial amounts 
of data are collected during drug exposure by local investigators for assessment of 
adverse effects.  This may facilitate the study of rare diseases, particularly if the 
disorder has been identified in advance and has a plausible biological rationale.  
However care must be taken with post hoc analyses of databases with multiple 
events as statistically “significant” associations may occur by chance.  In 
EVOLVE, calcific uremic arteriolopathy (CUA) occurred infrequently, but 
cinacalcet reduced its incidence (relative hazard 0.31, 95% CI 0.13 to 0.79) (24).  
Predictors of CUA included allocation to placebo, female sex, higher body mass 
index, hypertension, prior PTX and prior tobacco use.  In addition, use of vitamin 
K antagonists at time of CUA was significantly higher than use in patients without 
CUA. 
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Lesson.   
1. RCTs can provide important information on rare diseases, particularly when a 
large cohort of patients is followed in the trial at relatively high risk for 
developing the rare disease (25), and for which a plausible biological rationale 
exists. 
Biomarkers.  Collection and storage of blood for subsequent biomarker 
measurement may contribute to the understanding of disease pathogenesis (26), 
and in a large RCT the incremental cost of collecting patient samples is relatively 
low.  Because of the long duration of trials (EVOLVE started in August 2006 and 
finished in January 2012, with primary publication of trial results in November 
2012) and the potential for biomarker research to be published during the 
execution of the trial, we did not designate which biomarkers would be measured 
until after the trial was completed.  From 2007-2011 data had accumulated in 
patients with advance CKD and ESRD that serum fibroblast growth factor 23 (FGF 
23) concentrations were elevated and were associated with mortality, left 
ventricular hypertrophy and cardiovascular events independent of serum 
phosphate, PTH and a variety of demographic and other clinical factors (27, 28).   
Sixty four percent of patients assigned to cinacalcet had ≥ 30% reduction in serum 
FGF23 concentrations from baseline to week 20 compared to 28% of the placebo 
group (29).  Among patients randomized to cinacalcet ≥ 30% reduction in FGF23 
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was associated with a significant reduction in the composite CV endpoint (relative 
hazard 0.82, 95% CI 0.69 to  0.98) (29). This non-randomized analysis generates 
the hypothesis that FGF23 plays a role in the pathogenesis of CV events in CKD, 
and the deleterious effects of FGF23 might be ameliorated by cinacalcet. 
Lesson.   
1. Collection of serum for biomarker investigation in a large RCT should be 
undertaken because it facilitates rapid testing of hypotheses generated after the 
RCT started, and creation of new hypotheses. 
Interpretation of clinical benefits. Trials should not be judged by the result of a 
single analysis and a single p- value, but inferences should be made on the totality 
of the data. The decision to prescribe cinacalcet should be informed by 
consideration of the benefits to risks ratio in individual patients. Cinacalcet is 
approved for the treatment of secondary HPT and in EVOLVE it was effective in 
preventing severe unremitting HPT. Treatment effects of cinacalcet on fracture 
rates were similar to those on CV events using unadjusted ITT ,multi variable 
adjusted ITT, and censoring at co-interventions that reduce PTH;age was also an 
effect modifier(30).A recent review has examined the clinical and practical use of 
calcimimetics in dialysis patients(31).An economic evaluation of cinacalcet in the 
United States has been reported(32). 
19 
 
  
 
Conclusions  
The EVOLVE trial provides multiple lessons in the planning, execution, analysis 
and interpretation of RCTs in CKD/ESRD.  These include deciding upon, defining 
and analyzing outcomes, responding to lower than predicted event rates, taking 
account of non-adherence and of co-interventions, subgroup effects, capture of rare 
diseases, biomarkers, and interpretation of benefits to harms ratio. 
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Table 1.  Lessons from EVOLVE concerning choice and definition of composite 
endpoints. 
 
1.  Primary composite endpoints should include events resulting from 
pathophysiologic pathways highly likely to be influenced by the intervention. 
2. A.  Heart failure in patients receiving dialysis occurs frequently but is often 
misdiagnosed by nephrologists even when the definition includes manifestations of 
pulmonary edema.  Sample size should be increased to take account of 
misclassification. 
B. Randomized clinical trials in CKD or ESRD that include an endpoint of 
heart failure should include focused education to ensure accurate identification of 
heart failure events. 
C. A classification system of heart failure based on patient-reported dyspnea 
assessed pre- and post-ultrafiltration in conjunction with echocardiography may be 
useful (6), but requires validation. 
3.  Selection bias associated with PTX necessitated a more holistic approach to the 
definition of severe unremitting hyperparathyroidism. 
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Table 2.  Lessons from EVOLVE concerning imbalance in baseline 
covariates. 
1.  Randomization is not guaranteed to prevent significant imbalance in     
baseline clinical characteristics (even for a trial with nearly 4000 subjects). 
2.  RCTs in CKD/ESRD should employ both multivariable adjusted ITT and 
unadjusted ITT in the analysis of the primary outcome. 
3.  If there is risk of imbalance of baseline covariates, multivariable adjusted 
ITT should be used as the primary analysis on which the trial is judged (18). 
4. If participants across a broad age range are enrolled, stratification by age    
 may be advisable, as age is an important determinant of many outcomes.  A 
 similar argument could be made for other key covariates (e.g., baseline 
 blood pressure or proteinuria) depending on the outcome(s) of interest. 
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Table 3. The Treatment Effect on the Primary Composite Cardiovascular Endpoint:   
               Prespecified Sensitivity Analyses (1, 20) 
 
 
 
HRHRHR ((%% CI) p-value 
Unadjusted ITT 0.93 (0.85, 1.02) 0.112 
MV adjusted ITT 0.88 (0.79, 0.97) 0.008 
Inverse probability of 
censoring weights 
0.81 (0.70, 0.92) 0.031 
Censor at PTX 0.90 (0.82,0.99) 0.029 
Censor at KT 0.90 (0.82. 0.99) 0.032 
Censor at Commercial 
Cinacalcet Use 
0.90 (0.82. 0.99) <0.001 
 
Censor at PTX, 
Commercial Cinacalcet, or 
KT 
0.84 (0.76, 0.93) <0.001 
Age  < 65 years 0.99 (0.88, 1.11) Interaction 0.007 
Age  ≥ 65 years 0.74 (0.63, 0.86)  
 
 
HR:  hazard ratio; CI:  confidence intervals 
ITT:  intention to treat; MV:  multivariable 
PTX:  parathyroidectomy; KT:  Kidney transplant 
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Table 4.  Lessons from EVOLVE concerning the analytic plan for non-adherence 
and co-interventions. 
1.  Commercial availability of study drug can make drop-in a serious problem as 
the use of commercial drug off protocol limits the capacity of the trial to observe a 
treatment effect.  During trial execution major efforts are required to reduce use of 
commercial drug and an analytic plan needs to take account of drop-in.  
2. A.  Discontinuation of study drug is likely in a long-term trial in patients on 
dialysis, and generous estimates should be incorporated into power calculations.  
B.  Longer follow-up time does not necessarily increase study power. 
3.  An analytic plan to take account of non-adherence must be pre-specified.  
IPCW maybe the best method to account for non-adherence particularly if 
determinants of non-adherence are well established. 
4.  It is necessary to take account of the impact of co-interventions that limit 
assessment of the trial’s main treatment effect.  Depending on the nature of the 
intervention, it may be wise to censor follow-up time after the intervention, or to 
incorporate the intervention into a composite endpoint (e.g., initiation of dialysis in 
a trial aiming to slow progression of CKD). 
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Table 5.  Lessons from EVOLVE concerning the credibility of sub-group effects. 
A subgroup effect is credible (23) when  
(a)  it is relatively large and highly statistically significant,  
(b)  it is one of a small group of prespecified hypotheses tested,  
(c)  the test of treatment x subgroup interaction  is significant,  
(d)  The sub-group effect is consistent with other reports (33) 
(e)  The sub-group effect is consistent across related outcomes (19)  
(f) the biological rationale is plausible.   
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LEGENDS 
Figure 1. Four main causes of reduction in statistical power that occurred in 
EVOLVE 
 
 
 
Figure 2  Inverse Probability of Censoring Weight (IPCW) 
 
• IPCW method creates a scenario of missing follow-up data by censoring the 
follow-up of each subject at the time of stopping investigational product (IP) 
(ie, weight=0 for time periods afterwards) 
 
• For subjects with similar characteristics that did not stop IP, IPCW method 
assigns bigger weights to “to subjects with similar characteristics that 
dobserved without stopping IP 
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